{{Rsnum
|rsid=10754339
|Gene=VTCN1
|Chromosome=1
|position=117147650
|Orientation=plus
|GMAF=0.2388
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=VTCN1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 85.0 | 14.2 | 0.9
| HCB | 85.4 | 14.6 | 0.0
| JPT | 80.5 | 18.6 | 0.9
| YRI | 8.2 | 33.3 | 58.5
| ASW | 12.3 | 43.9 | 43.9
| CHB | 85.4 | 14.6 | 0.0
| CHD | 83.5 | 16.5 | 0.0
| GIH | 76.2 | 23.8 | 0.0
| LWK | 7.3 | 40.0 | 52.7
| MEX | 81.0 | 17.2 | 1.7
| MKK | 18.7 | 45.8 | 35.5
| TSI | 84.3 | 14.7 | 1.0
| HapMapRevision=28
}}
[[rs10754339]] is a SNP in the V-set domain containing T cell activation inhibitor 1 [[VTCN1]] gene, which is also known as B7-H4. 

A study of 500 Chinese Han women with breast cancer (and an equal number of matched controls) concluded that the [[rs10754339]](A;G) genotype and G allele showed a significantly increased risk of [[breast cancer]] (odds ratio 1.455, CI: 1.119-1.892, and 1.325, CI: 1.073-1.637, respectively). Additionally, the [[rs10754339]](G;G) genotype was significantly associated with lymph node metastasis and PR status, and the G allele and the (A;G) genotype were respectively associated with lymph node metastasis and ER status.{{PMID|19903360|OA=1
}}

{{PMID Auto
|PMID=19756043
|Title=A simple and efficient algorithm for genome-wide homozygosity analysis in disease.
|OA=1
}}

{{PMID Auto
|PMID=24125968
|Title=An investigation of the effects of FGFR2 and B7-H4 polymorphisms in breast cancer
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}